Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

Leukemia Research

Volumn 31, Issue 11, 2007, Pages 1503-1509

  Elliott, M A ^a   Verstovsek, S ^b   Dingli, D ^a   Schwager, S M ^a   Mesa, R A ^a   Li, C Y ^a   Tefferi, A ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Monocytosis; Myelofibrosis; Myeloproliferative disorder; Prognosis; Survival

Indexed keywords

ADULT; ARTICLE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTOSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; MYELOFIBROSIS; PROGNOSIS;

EID: 35448969338     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.12.025     Document Type: Article

References (24)

1. Vardiman J.W., Brunning R.D., and Harris N.L. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues (2001), International Agency for Research on Cancer (IARC) Press, Lyon, France 17-44
2. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
3. Mesa R.A., Silverstein M.N., Jacobsen S.J., Wollan P.C., and Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study, 1976-1995. Am J Hematol 61 (1999) 10-15
4. Reilly J.T. Idiopathic myelofibrosis: pathogenesis, natural history and management. [Review] [99 refs]. Blood Rev 11 (1997) 233-242
5. Barosi G., Berzuini C., Liberato L.N., Costa A., Polino G., and Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia [see comments]. Br J Haematol 70 (1988) 397-401
6. Visani G., Finelli C., Castelli U., Petti M.C., Ricci P., Vianelli N., et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75 (1990) 4-9
7. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
8. Cervantes F., Barosi G., Demory J.L., Reilly J., Guarnone R., Dupriez B., et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102 (1998) 684-690
9. Dingli D., Schwager S.M., Mesa R.A., Li C.Y., and Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. Cancer 106 (2006) 623-630
10. Cervantes F., Pereira A., Esteve J., Rafel M., Cobo F., Rozman C., et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 97 (1997) 635-640
11. Guardiola P., Anderson J.E., Bandini G., Cervantes F., Runde V., Arcese W., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 93 (1999) 2831-2838
12. Deeg H.J., Gooley T.A., Flowers M.E., Sale G.E., Slattery J.T., Anasetti C., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
13. Onida F., Kantarjian H.M., Smith T.L., Ball G., Keating M.J., Estey E.H., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (2002) 840-849
14. Beran M., Shen Y., Onida F., et al. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leukemia Lymphoma 47 (2006) 417-423
15. Barosi G., Ambrosetti A., Finelli C., Grossi A., Leoni P., Liberato N.L., et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 104 (1999) 730-737
16. Tefferi A., Dingli D., Li C.Y., and Dewald G.W. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 104 (2005) 1656-1660
17. Kroger N., Zabelina T., Schieder H., Panse J., Ayuk F., Stute N., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128 (2005) 690-697
18. Tefferi A., and Gilliland D.G. Classification of myeloproliferative disorders: from dameshek towards a semi-molecular system. Best Practice Res Clin Haematol 19 (2006) 365-385
19. Kralovics R., Passamonti F., Buser A.S., Soon-Siong T., Tiedt R., Passweg J.R., et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New Engl J Med 352 (2005) 1779-1790
20. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
21. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23 (2005) 8520-8530
22. Arellano-Rodrigo E., Alvarez-Larran A., Reverter J.C., Villamor N., Colomer D., and Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91 (2006) 169-175
23. Johan M., Goodeve A.C., Bowen D.T., et al. JAK2V617F mutation is uncommon in chronic myelomonocytic leukaemia. Br J Haematol 130 (2005) 964
24. Onida F., and Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 3 (2004) 218-226